Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
MaaT Pharma
Biotech
MaaT posts 18-month data showing 'clear OS advantage' in aGvHD
The microbiome biotech has touted long-term data as proof it’s on track to launch the drug in acute graft-versus-host disease in two years’ time.
James Waldron
Apr 15, 2024 7:05am
FDA drops resistance to fecal pooling, clears MaaT for phase 3
Apr 24, 2023 6:10am
After 18-month hold, MaaT sees end to impasse with FDA
Feb 3, 2023 9:55am
FDA declines to free MaaT's microbiome drug from a clinical hold
Aug 10, 2022 1:47pm
MaaT wraps up microbiome trial early to power into phase 2/3
Jan 24, 2022 7:20am
MaaT links microbiome drug to GvHD responses, plans phase 3
Mar 17, 2021 9:30am